文献速递血栓与止血

既往接受旁路制剂或凝血因子浓缩物预防治疗的血友病A或B患者换用Fitusiran预防治疗:ATLAS-PPX试验

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial.
PubMed 文献 · Blood · 2024-01-01

这项3期开放标签研究评估了Fitusiran预防治疗在既往接受旁路制剂(BPA)或凝血因子浓缩物(CFC)预防治疗的≥12岁男性血友病A或B患者(伴或不伴抑制物)中的疗效与安全性。80例入组者中65例(抑制物19例、非抑制物46例)纳入年化出血率(ABR)分析;换用每月一次80 mg Fitusiran后ABR较BPA/CFC预防治疗显著降低(抑制物组降低79.7%,P=.0021;非抑制物组降低46.4%,P=.0598),2例(3.0%)发生可疑或确诊血栓栓塞事件。

要点

  • 换用每月一次80 mg Fitusiran后,抑制物组估计平均ABR较BPA/CFC预防治疗降低79.7%(P=.0021)。
  • 非抑制物组估计平均ABR较BPA/CFC预防治疗降低46.4%(P=.0598),未达统计学显著。
  • Fitusiran治疗期间41例(63.1%)无治疗性出血,BPA/CFC期间为11例(16.9%)。

核心结论

  • 每月一次Fitusiran预防治疗较BPA/CFC预防治疗显著减少伴或不伴抑制物的血友病A或B患者的出血事件,不良事件总体与既往已知的Fitusiran风险一致。

研究设计与样本

  • 3期开放标签研究,纳入≥12岁男性血友病A或B患者(伴或不伴抑制物),先继续既往BPA/CFC预防治疗6个月,再换用每月一次80 mg Fitusiran预防治疗7个月(起效期和疗效期)。
  • 共入组80例,其中65例(抑制物19例、非抑制物46例)符合ABR分析条件。
  • 主要终点为BPA/CFC预防治疗期与Fitusiran疗效期的年化出血率(ABR),次要终点包括自发性ABR(AsBR)和关节ABR(AjBR),并评估安全性与耐受性。
  • 试验在www.ClinicalTrials.gov注册,注册号#NCT03549871。

主要发现

  • 抑制物组:观察到的中位ABR在BPA/CFC预防治疗期为6.5(IQR 2.2-19.6),在Fitusiran疗效期为0.0(IQR 0.0-0.0);估计平均ABR较BPA/CFC降低79.7%(P=.0021)。
  • 非抑制物组:观察到的中位ABR在BPA/CFC预防治疗期为4.4(IQR 2.2-8.7),在Fitusiran疗效期为0.0(IQR 0.0-2.7);估计平均ABR较BPA/CFC降低46.4%(P=.0598)。
  • Fitusiran治疗期间41例(63.1%)无治疗性出血,BPA/CFC预防治疗期间为11例(16.9%)。
  • 中位AsBR和AjBR在BPA/CFC预防治疗期均为2.2,在Fitusiran疗效期均为0.0。
  • 2例(3.0%)在Fitusiran治疗期间发生可疑或确诊血栓栓塞事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, targets antithrombin to rebalance hemostasis in people with hemophilia A or B (PwHA/B), irrespective of inhibitor status. This phase 3, open-label study evaluated the efficacy and safety of fitusiran prophylaxis in males aged ≥12 years with hemophilia A or B, with or without inhibitors, who received prior bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis. Participants continued their prior BPA/CFC prophylaxis for 6 months before switching to once-monthly 80 mg fitusiran prophylaxis for 7 months (onset and efficacy periods). Primary end point was annualized bleeding rate (ABR) in the BPA/CFC prophylaxis and fitusiran efficacy period. Secondary end points included spontaneous ABR (AsBR) and joint ABR (AjBR). Safety and tolerability were assessed. Of 80 enrolled participants, 65 (inhibitor, n = 19; noninhibitor, n = 46) were eligible for ABR analyses. Observed median ABRs were 6.5 (interquartile range [IQR], 2.2-19.6)/4.4 (IQR, 2.2-8.7) with BPA/CFC prophylaxis vs 0.0 (IQR, 0.0-0.0)/0.0 (IQR, 0.0-2.7) in the corresponding fitusiran efficacy period. Estimated mean ABRs were substantially reduced with fitusiran by 79.7% (P = .0021) and 46.4% (P = .0598) vs BPA/CFC prophylaxis, respectively. Forty-one participants (63.1%) experienced 0 treated bleeds with fitusiran vs 11 (16.9%) with BPAs/CFCs. Median AsBR and AjBR were both 2.2 with BPA/CFC prophylaxis and 0.0 in the fitusiran efficacy period. Two participants (3.0%) experienced suspected or confirmed thromboembolic events with fitusiran. Once-monthly fitusiran prophylaxis significantly reduced bleeding events vs BPA/CFC prophylaxis in PwHA/B, with or without inhibitors, and reported adverse events were generally consistent with previously identified risks of fitusiran. This trial was registered at www.ClinicalTrials.gov as #NCT03549871.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kenet G, Nolan B, Zulfikar B, et al. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood. 2024. PMID: 38452197. doi:10.1182/blood.2023021864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。